Last reviewed · How we verify
RGX-104
At a glance
| Generic name | RGX-104 |
|---|---|
| Sponsor | Inspirna, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer (PHASE1)
- Abequolixron (RGX-104) and Durvalumab in Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RGX-104 CI brief — competitive landscape report
- RGX-104 updates RSS · CI watch RSS
- Inspirna, Inc. portfolio CI